Treatment strategy of Alzheimer disease: Pause of clinical trials of Aβ vaccine and next steps

Brain and Nerve

Volumn 62, Issue 7, 2010, Pages 659-666

  Kuzuhara, Shigeki ^a  

^a SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Alzheimer disease; Amyloid; Prevention; Tau; Treatment; Vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COMPLEMENTARY DNA; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; PLACEBO; PRESENILIN 1; TAU PROTEIN; APOLIPOPROTEIN E4; PRESENILIN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; AUTOPSY; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KAPLAN MEIER METHOD; MENINGOENCEPHALITIS; MOUSE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; SENILE PLAQUE; SURVIVAL RATE; TRANSGENIC MOUSE; TREATMENT OUTCOME; VACCINATION; ANIMAL; BRAIN; CLINICAL TRIAL (TOPIC); GENETICS; IMMUNOLOGY; METABOLISM; MUTATION; NERVE DEGENERATION; PATHOLOGY;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEIN E4; BRAIN; CLINICAL TRIALS AS TOPIC; HUMANS; MENINGOENCEPHALITIS; MICE; MUTATION; NERVE DEGENERATION; NEUROFIBRILLARY TANGLES; PRESENILINS; TAU PROTEINS; AMYLOID BETA-PEPTIDES;

EID: 77955351154     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890, 1984 (Pubitemid 14104991)
2. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999
3. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, et al: Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372: 216-223, 2008 (Pubitemid 351978111)
4. Hardy JA, Higgins GA: Alzheimer's disease: the amyloid cascade hypothesis. Science 256: 184-185, 1992
5. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002 (Pubitemid 34790756)
6. Senior K: Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 1: 3, 2002
7. Ihara Y, Abraham C, Selkoe J: Antibodies to paired helical filaments in Alzheimer's disease do not recognize normal brain protein. Nature 304: 727-730, 1983 (Pubitemid 13037718)
8. Mann DM, Esiri MM: The site of the earliest lesions of Alzheimer's disease. N Engl J Med 318: 789-790, 1988 (Pubitemid 18090270)
9. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706, 1991 (Pubitemid 21912142)
10. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, et al: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248: 1124-1126, 1990 (Pubitemid 20189869)
11. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760, 1995
12. Levy-Lahad E, Wijsman EM, Nemens E, Anderson L, Goddard KA, et al: A familial Alzheimer's disease locus on chromosome 1. Science 269: 970-973, 1995
13. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K: Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541: 163-166, 1991
14. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923, 1993
15. Reiman EM, Chen K, Liu X, Bandy D, Yu M, et al: Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 106: 6820-6825, 2009
16. Drzezga, A, Grimmer T, Henriksen G, Mühlau M, Perneczky R, et al: Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72: 1487-1494, 2009
17. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al: Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373: 523-527, 1995
18. Hsiao KK, Borchelt DR, Olson K, Johannsdottir R, Kitt C, et al: Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 15: 1203-1218, 1995
19. Ashe KH: Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem 8: 301-308, 2001 (Pubitemid 34037573)
20. Schenk D: Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 3: 824-828, 2002
21. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, et al: Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8: 1270-1275, 2002 (Pubitemid 35373559)
22. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, et al: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562, 2005 (Pubitemid 40617691)
23. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003 (Pubitemid 36460079)
24. Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussá F: Neuropathology and pathogenesis of encephalitis following amyloid beta immunization in Alzheimer's disease. Brain Pathol 14: 11-20, 2004 (Pubitemid 38200585)
25. Masliah E, Hansen L, Adame A, Crews L, Bard F, et al: Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 64: 129-131, 2005 (Pubitemid 40082949)
26. St George-Hyslop PH, Morris JC: Will anti-amyloid therapies work for Alzheimer's disease? Lancet 372: 180-182, 2008
27. 1-42 trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 302: 1796-1802, 2009
28. Risacher SL, Saykin AJ, West JD, Shen L, Firpil HA, et al: Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res, 6: 347-361, 2009
29. Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, et al: Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 74: 201-209, 2010